Head-To-Head Review: RYTHM (RYM) vs. Its Peers

RYTHM (NASDAQ:RYM) is one of 903 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare RYTHM to similar businesses based on the strength of its valuation, dividends, risk, analyst recommendations, earnings, profitability and institutional ownership.

Profitability

This table compares RYTHM and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
RYTHM Competitors	-2,299.87%	-222.98%	-17.45%

Earnings and Valuation

This table compares RYTHM and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
RYTHM	$17.28 million	-$33.26 million	-2.44
RYTHM Competitors	$4.38 billion	$3.12 billion	547.15

RYTHM’s competitors have higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

RYTHM has a beta of 9.44, indicating that its stock price is 844% more volatile than the S&P 500. Comparatively, RYTHM’s competitors have a beta of -3.18, indicating that their average stock price is 418% less volatile than the S&P 500.

Insider & Institutional Ownership

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for RYTHM and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1	0	0	0	1.00
RYTHM Competitors	7584	13648	25432	998	2.42

As a group, “Pharmaceuticals” companies have a potential upside of 30.14%. Given RYTHM’s competitors stronger consensus rating and higher probable upside, analysts clearly believe RYTHM has less favorable growth aspects than its competitors.

Summary

RYTHM competitors beat RYTHM on 9 of the 13 factors compared.

RYTHM Company Profile

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.